Novartis posts strong growth but warns of tough year ahead
January 27, 2011Sales and Marketing 2010 pharma results, Novartis
Novartis has posted strong sales growth for the full year but its chief executive warns of ‘headwinds in 2011’ as …
Prime Minister uses online network to rally doctors around reforms
January 27, 2011Sales and Marketing Doctors.net.uk, GPs, commissioning, david cameron, docotrs, prime minister
Prime Minister David Cameron has made exclusive use of Doctors.net.uk, the UK’s largest network of medical professionals, to reinforce his …
NICE decides to back Abilify in schizophrenia
January 27, 2011Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia
NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …
Double Helix Consulting expands
January 26, 2011Sales and Marketing Clara Loveman, Double Helix, Dr Clive Whitcher, Dr Laurence Wild, appointment, sales and marketing
Double Helix Consulting has appointed three new executives to its growing global team – Clara Loveman, Dr Clive Whitcher and …
The Evolving Role of European Regulatory Agencies
January 26, 2011Research and Development Consultancy, regulatory affairs, regulatory agencies
The regulatory landscape can change in a very short period of time. Matthew Walker, Senior Regulatory Affairs Executive at TRAC …
Pharma-biotech partnerships: creative approaches to doing the deal
January 26, 2011Research and Development Susan Aldridge, biotech, biotech partnerships, pharma partnering
Research and development partnerships between big pharma and the biotech sector are now a vital component in bringing new medicines …
Sanofi buys into cancer antibody research
January 26, 2011Research and Development Cancer, Oxford Biotherapeutics, Sanofi, Sanofi-Aventis, antibody drug conjugate, cancer research
Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …
J&J posts negative growth as pharma sales stall
January 26, 2011Sales and Marketing 2010 pharma results, J&J, JJ, Johnson and Johnson, Remicade, Risperdal Consta
Falling fourth quarter sales of Risperdal Consta and Remicade capped a year to forget for Johnson and Johnson. The company’s …
Dr Marie-Paule Richard joins AiCuris as CMO
January 26, 2011Research and Development AiCuris, Dr Marie-Paule Richard, appointment, research and development
German clinical research company AiCuris has appointed Dr Marie-Paule Richard as chief medical officer. She has over 24 years of …
Eisai sepsis drug fails in phase III
January 26, 2011Research and Development, Sales and Marketing Eisai, eritoran, perampanel, sepsis
A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …
NHS competition will prevent postcode lottery, says Lansley
January 25, 2011NHS, NHS reforms, postcode prescribing
The government has pledged that value-based competition in the NHS will create “the very opposite of the postcode lottery”, following …
Amgen signs $1 billion cancer biotech deal
January 25, 2011Research and Development Amgen, BioVex, OncoVEXGM-CSF, cancer vaccine
Amgen is set to pay $1 billion for US biotech firm BioVex, in the process gaining access to its novel …
David Jukes promoted to president of Univar Europe
January 25, 2011Manufacturing and Production David Jukes, John van Osch, manufacturing and production, univar
Chemical distributor Univar has promoted David Jukes to president of its European operations. He replaces John van Osch who is …
Genzyme plans new Belgium facility
January 25, 2011Manufacturing and Production Belgium, Genzyme, Lumizyme, Myozyme, Pompe disease, Sanofi-Aventis, alglucosidase alfa
US rare disease drug specialist Genzyme, the subject of a hostile takeover offer from France’s Sanofi-Aventis, says that it will …
Bio and clinical plants feature in 2011 FOYA honours
January 25, 2011Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing
Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …
GSK skin cancer drugs moves into phase III
January 25, 2011Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer
GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …
SHL GM Frank Isaksson to speak at the 2011 Injectable Drug Delivery Conference
January 25, 2011Manufacturing and Production, Medical Communications auto injector, autoinjector, frank isaksson, injectable drug delivery
With a steadily increasing number of biologics coming to market, the demand for auto injectors and similar devices continues to …
Axon makes US appointment
January 24, 2011Medical Communications AXON Communications, Mark Khan, appointment, medical communications
Richmond, UK-based comms agency Axon Communications has expanded its stateside operations, appointing Mark Khan as VP of client services and …
Digital Pharma: Pfizer UK’s online surgery (case study)
January 24, 2011Medical Communications Digital Pharma blog, Facebook advertising, Google Adwords, ManMOT, PR, Pfizer, Twitter, blogs, male health
Pfizer UK’s online male health clinic Man MOT was launched last summer to offer men confidential advice and information about …
Novartis MS drug steals march over Merck rival
January 24, 2011Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis
Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
